HALOZYME THERAPEUTICS, INC. (HALO) Share buybacks
- Total buybacks · last 12 months (USD): Value $371.61M; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..
Share buybacks
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $371.61M | Trailing-year cash paid for share repurchases. Period ending 2026-06-30. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 371.61M USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-06-30 | $371.61M | (m) | (m) |
| 2025-12-31 | $342.37M | (m) | (m) |
| 2025-09-30 | $592.37M | (m) | (m) |
| 2025-06-30 | $553.49M | (m) | (m) |
| 2024-12-31 | $250.00M | (m) | (m) |
| 2024-09-30 | $252.30M | (m) | (m) |
| 2024-06-30 | $252.30M | (m) | (m) |
| 2024-03-31 | $252.30M | (m) | (m) |
| 2023-12-31 | $402.38M | (m) | (m) |
| 2023-09-30 | $150.08M | (m) | (m) |
| 2023-06-30 | $350.08M | (m) | (m) |
| 2023-03-31 | $350.08M | (m) | (m) |
| 2022-12-31 | $200.00M | (m) | (m) |
| 2022-09-30 | $360.32M | (m) | (m) |
| 2022-08-31 | (m) | (m) | (m) |
| 2022-06-30 | $225.04M | (m) | (m) |
| 2022-03-31 | $273.88M | (m) | (m) |
| 2021-12-31 | $350.06M | (m) | (m) |
| 2021-09-30 | $229.88M | (m) | (m) |
| 2021-06-30 | $221.57M | (m) | (m) |
| 2021-03-31 | $174.72M | (m) | (m) |
| 2020-12-31 | $150.12M | (m) | (m) |
| 2020-09-30 | $309.97M | (m) | (m) |
| 2020-06-30 | $253.57M | (m) | (m) |
| 2020-03-31 | $251.57M | (m) | (m) |
| 2019-12-31 | $200.00M | (m) | (m) |
| 2019-11-30 | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | (m) | (m) |
| 2017-12-31 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |